BCG Vaccination: A Potential Tool Against COVID-19 and COVID-19-like Black Swan Incidents

Overview

Journal Int Immunopharmacol

Specialties Allergy & Immunology
Pharmacology

Date 2022 May 21

PMID 35597119

Authors

Wenping Gong

Yingqing Mao

Yuexi Li

Yong Qi

Affiliations

Soon will be listed here.

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19), and its variants have brought unprecedented impacts to the global public health system, politics, economy, and other fields. Although more than ten COVID-19 specific vaccines have been approved for emergency use, COVID-19 prevention and control still face many challenges. Bacille Calmette-Guérin (BCG) is the only authorized vaccine used to fight against tuberculosis (TB), it has been hypothesized that BCG may prevent and control COVID-19 based on BCG-induced nonspecific immune responses. Herein, we summarized: 1) The nonspecific protection effects of BCG, such as prophylactic protection effects of BCG on nonmycobacterial infections, immunotherapy effects of BCG vaccine, and enhancement effect of BCG vaccine on unrelated vaccines; 2) Recent evidence of BCG's efficacy against SARS-COV-2 infection from ecological studies, analytical analyses, clinical trials, and animal studies; 3) Three possible mechanisms of BCG vaccine and their effects on COVID-19 control including heterologous immunity, trained immunity, and anti-inflammatory effect. We hope that this review will encourage more scientists to investigate further BCG induced non-specific immune responses and explore their mechanisms, which could be a potential tool for addressing the COVID-19 pandemic and COVID-19-like "Black Swan" events to reduce the impacts of infectious disease outbreaks on public health, politics, and economy.

Citing Articles

The Impact of COVID-19 on the Tuberculosis Features in a Romanian Pneumology Hospital.

Popovici G, Georgescu C, Vasile C, Mihailov O, Vasile M, Arbune M J Multidiscip Healthc. 2024; 17:2489-2498.

PMID: 38799014 PMC: 11128235. DOI: 10.2147/JMDH.S463859.

Cutaneous Leishmaniasis Hampers COVID-19: A Controlled Cross-Sectional Study in High-Burden Endemic Areas of Iran.

Bamorovat M, Sharifi I, Shafiei Bafti M, Agha Kuchak Afshari S, Aflatoonian M, Karamoozian A J Epidemiol Glob Health. 2024; 14(1):142-153.

PMID: 38190050 PMC: 11043327. DOI: 10.1007/s44197-023-00179-0.

Triple Burden: The Incorrigible Threat of Tuberculosis, HIV, and COVID-19.

Gupta P, Sandhu D, Gupta V, Singhal L Infect Disord Drug Targets. 2023; 24(4):1-7.

PMID: 37937570 DOI: 10.2174/0118715265259959231031104820.

Excluding Participants With Mycobacteria Infections From Clinical Trials: A Critical Consideration in Evaluating the Efficacy of BCG Against COVID-19.

Gong W, Du J J Korean Med Sci. 2023; 38(42):e343.

PMID: 37904656 PMC: 10615642. DOI: 10.3346/jkms.2023.38.e343.

Exploring BCG vaccination as a novel approach to prevent recurrent herpes labialis.

Gong W, Du J, Zhuang L, Wu X EClinicalMedicine. 2023; 65:102279.

PMID: 37876999 PMC: 10590831. DOI: 10.1016/j.eclinm.2023.102279.

References

Lodmell D, Ewalt L . Enhanced resistance against encephalomyocarditis virus infection in mice, induced by a nonviable Mycobacterium tuberculosis oil-droplet vaccine. Infect Immun. 1978; 19(1):225-30. PMC: 414071. DOI: 10.1128/iai.19.1.225-230.1978. View

Khanum I, Kumar L, Awan S, Jamil B . Severity of COVID-19 in bacillus Calmette-Guérin vaccinated population. Clin Exp Vaccine Res. 2021; 10(3):276-281. PMC: 8511583. DOI: 10.7774/cevr.2021.10.3.276. View

Daulatabad D, Pandhi D, Singal A . BCG vaccine for immunotherapy in warts: is it really safe in a tuberculosis endemic area?. Dermatol Ther. 2016; 29(3):168-72. DOI: 10.1111/dth.12336. View

Higgins J, Soares-Weiser K, Lopez-Lopez J, Kakourou A, Chaplin K, Christensen H . Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ. 2016; 355:i5170. PMC: 5063034. DOI: 10.1136/bmj.i5170. View

Zhang T, Zhong B . Meeting the potential emergency global drug supply challenge of hydroxychloroquine for COVID-19. Med Drug Discov. 2020; 5:100036. PMC: 7144509. DOI: 10.1016/j.medidd.2020.100036. View

Netea M, Joosten L, Latz E, Mills K, Natoli G, Stunnenberg H . Trained immunity: A program of innate immune memory in health and disease. Science. 2016; 352(6284):aaf1098. PMC: 5087274. DOI: 10.1126/science.aaf1098. View

Moorlag S, van Deuren R, van Werkhoven C, Jaeger M, Debisarun P, Taks E . Safety and COVID-19 Symptoms in Individuals Recently Vaccinated with BCG: a Retrospective Cohort Study. Cell Rep Med. 2020; 1(5):100073. PMC: 7405881. DOI: 10.1016/j.xcrm.2020.100073. View

Valeras A . COVID-19: Complexity and the Black Swan. Fam Syst Health. 2020; 38(2):221-223. DOI: 10.1037/fsh0000486. View

Wang Q, Chen L, Li J, Zheng J, Cai N, Gong P . A novel recombinant BCG vaccine encoding eimeria tenella rhomboid and chicken IL-2 induces protective immunity against coccidiosis. Korean J Parasitol. 2014; 52(3):251-6. PMC: 4096635. DOI: 10.3347/kjp.2014.52.3.251. View

10.

Dos Santos J, Vilela Teodoro Silva M, Ribeiro-Dias F, Joosten L . Non-specific effects of BCG in protozoal infections: tegumentary leishmaniasis and malaria. Clin Microbiol Infect. 2019; 25(12):1479-1483. DOI: 10.1016/j.cmi.2019.06.002. View

11.

Hupert N, Marin-Hernandez D, Gao B, Aguas R, Nixon D . Heterologous vaccination interventions to reduce pandemic morbidity and mortality: Modeling the US winter 2020 COVID-19 wave. Proc Natl Acad Sci U S A. 2022; 119(3). PMC: 8784160. DOI: 10.1073/pnas.2025448119. View

12.

Karabay O, Kose O, Tocoglu A, Uysal B, Dheir H, Yaylaci S . Investigation of the frequency of COVID-19 in patients treated with intravesical BCG. Rev Assoc Med Bras (1992). 2020; 66Suppl 2(Suppl 2):91-95. DOI: 10.1590/1806-9282.66.S2.91. View

13.

Ristori G, Faustman D, Matarese G, Romano S, Salvetti M . Bridging the gap between vaccination with Bacille Calmette-Guérin (BCG) and immunological tolerance: the cases of type 1 diabetes and multiple sclerosis. Curr Opin Immunol. 2018; 55:89-96. DOI: 10.1016/j.coi.2018.09.016. View

14.

Wassenaar T, Buzard G, Newman D . BCG vaccination early in life does not improve COVID-19 outcome of elderly populations, based on nationally reported data. Lett Appl Microbiol. 2020; 71(5):498-505. PMC: 9728116. DOI: 10.1111/lam.13365. View

15.

Haddad-Boubaker S, Othman H, Touati R, Ayouni K, Lakhal M, Ben Mustapha I . In silico comparative study of SARS-CoV-2 proteins and antigenic proteins in BCG, OPV, MMR and other vaccines: evidence of a possible putative protective effect. BMC Bioinformatics. 2021; 22(1):163. PMC: 7995392. DOI: 10.1186/s12859-021-04045-3. View

16.

Ohrui T, Nakayama K, Fukushima T, Chiba H, Sasaki H . [Prevention of elderly pneumonia by pneumococcal, influenza and BCG vaccinations]. Nihon Ronen Igakkai Zasshi. 2005; 42(1):34-6. DOI: 10.3143/geriatrics.42.34. View

17.

Kumar N, Padmapriyadarsini C, Rajamanickam A, Bhavani P, Nancy A, Jeyadeepa B . BCG vaccination induces enhanced frequencies of dendritic cells and altered plasma levels of type I and type III interferons in elderly individuals. Int J Infect Dis. 2021; 110:98-104. PMC: 8295056. DOI: 10.1016/j.ijid.2021.07.041. View

18.

Hidvegi M, Nichelatti M . Bacillus Calmette-Guerin vaccination Policy and Consumption of Ammonium Chloride-Enriched Confectioneries May Be Factors Reducing COVID-19 Death Rates in Europe. Isr Med Assoc J. 2020; 22(8):501-504. View

19.

Gallegos H, Rojas P, Sepulveda F, Zuniga A, San Francisco I . Protective role of intravesical BCG in COVID-19 severity. BMC Urol. 2021; 21(1):50. PMC: 8007648. DOI: 10.1186/s12894-021-00823-6. View

20.

Pathak S, Jolly M, Nandi D . Countries with high deaths due to flu and tuberculosis demonstrate lower COVID-19 mortality: roles of vaccinations. Hum Vaccin Immunother. 2021; 17(9):2851-2862. PMC: 8381816. DOI: 10.1080/21645515.2021.1908058. View